ArticlePloS one2016
Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 98 citations in OpenAlex.
- B and T cells in lung tissue are associated with smoking and forced vital capacity in idiopathic pulmonary fibrosis and familial pulmonary fibrosis.Respiratory research · 2026Article
- Prognostic role of serum CA-125 and CA19-9 in lung transplant candidates with interstitial lung disease: a retrospective cohort study.BMJ open respiratory research · 2025Article
- Deciphering the interplay: circulating cell-free DNA, signaling pathways, and disease progression in idiopathic pulmonary fibrosis.3 Biotech · 2025Review
- Article
- Targeting telomere dynamics with plant-derived compounds: Molecular strategies against aging.Current research in pharmacology and drug discovery · 2025Review
- BRD4: an effective target for organ fibrosis.Biomarker research · 2024Review
- Development of a Novel Biomarker for the Progression of Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2024Article
- Geniposide ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β/Smad and p38MAPK signaling pathways.PloS one · 2024Article
- Tertiary lymphoid structures and B-cell infiltration are IPF features with functional consequences.Frontiers in immunology · 2024Article
- Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF Progression.International journal of molecular sciences · 2023Review
- Targeted imaging of very late antigen-4 for noninvasive assessment of lung inflammation-fibrosis axis.EJNMMI research · 2023Article
- Trends and Outcomes in Lung Transplantation in Patients with and without Idiopathic Pulmonary Fibrosis in Spain during the Period 2016-2020.Healthcare (Basel, Switzerland) · 2023Article
- Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study.Life (Basel, Switzerland) · 2023Article
- A novel role of Fas in delaying cellular senescence.Heliyon · 2023Article
- Role of Mesenchymal Stem Cells and Extracellular Vesicles in Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2022Review
- Interstitial Lung Fibrosis Following COVID-19 Pneumonia.Diagnostics (Basel, Switzerland) · 2022Article
- Influence of chest wall conformation on spirometry parameters and outcome in mild-to-moderate idiopathic pulmonary fibrosis.Internal and emergency medicine · 2022Article
- Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.Respiratory research · 2022Article
- B7H3 expression and significance in idiopathic pulmonary fibrosis.The Journal of pathology · 2022Article
- Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break.Frontiers in medicine · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical course in idiopathic pulmonary fibrosis (IPF) is highly heterogeneous, with some patients having a slow progression and others an accelerated clinical and functional decline. This study aims to clinically characterize the type of progression in IPF and to investigate the pathological basis that might account for the observed differences in disease behavior. Clinical and functional data were analyzed in 73 IPF patients, followed long-time as candidates for lung transplantation. The forced vital capacity (FVC) change/year (< or ≥10% predicted) was used to define "slow" or "rapid" disease progression. Pathological abnormalities were quantified in the explanted lung of 41 out of 73 patients undergoing lung transplantation. At diagnosis, slow progressors (n = 48) showed longer duration of symptoms and lower FVC than rapid progressors (n = 25). Eleven slow and 3 rapid progressors developed an acute exacerbation (AE) during follow-up. Quantitative lung pathology showed a severe innate and adaptive inflammatory infiltrate in rapid progressors, markedly increased compared to slow progressors and similar to that observed in patients experiencing AE. The extent of inflammation was correlated with the yearly FVC decline (r = 0.52, p = 0.005). In conclusion an innate and adaptive inflammation appears to be a prominent feature in the lung of patients with IPF and could contribute to determining of the rate of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.